Gut, oral and nasal microbiota and Parkinson’s disease
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and in an effort to identify novel therapeutic target for this disease in recent years, human microbiota has attracted much interest. This paper briefly summarizes the main findings concerning the differences o...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Microbial Cell Factories |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12934-020-01313-4 |
id |
doaj-3f0015da2d7f458295f1aa11600e77f9 |
---|---|
record_format |
Article |
spelling |
doaj-3f0015da2d7f458295f1aa11600e77f92020-11-25T02:11:51ZengBMCMicrobial Cell Factories1475-28592020-02-011911710.1186/s12934-020-01313-4Gut, oral and nasal microbiota and Parkinson’s diseaseLiang Shen0Institute of Biomedical Research, Shandong University of TechnologyAbstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and in an effort to identify novel therapeutic target for this disease in recent years, human microbiota has attracted much interest. This paper briefly summarizes the main findings concerning the differences of human microbiome across several important mucosal interfaces, including nose, mouth, and gut between PD patients and controls as obtained from a total of 13 studies published since 2015, which covered a total of 943 PD patients and 831 matched controls from 6 countries. Overall, these studies supported the differences of gut microbiota between PD patients and matched controls, while significantly altered bacterial taxa among studies were not identical. Due to relatively limited number of available studies and covered patients, the associations between oral and nasal microbiota and PD remain inconclusive. The therapeutic and diagnostic potentials of gut microbiota for PD are discussed. More well-designed clinical studies recruiting large-scale PD patients are encouraged in future.http://link.springer.com/article/10.1186/s12934-020-01313-4Parkinson’s diseaseGut microbiotaOral microbiotaNasal microbiota |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liang Shen |
spellingShingle |
Liang Shen Gut, oral and nasal microbiota and Parkinson’s disease Microbial Cell Factories Parkinson’s disease Gut microbiota Oral microbiota Nasal microbiota |
author_facet |
Liang Shen |
author_sort |
Liang Shen |
title |
Gut, oral and nasal microbiota and Parkinson’s disease |
title_short |
Gut, oral and nasal microbiota and Parkinson’s disease |
title_full |
Gut, oral and nasal microbiota and Parkinson’s disease |
title_fullStr |
Gut, oral and nasal microbiota and Parkinson’s disease |
title_full_unstemmed |
Gut, oral and nasal microbiota and Parkinson’s disease |
title_sort |
gut, oral and nasal microbiota and parkinson’s disease |
publisher |
BMC |
series |
Microbial Cell Factories |
issn |
1475-2859 |
publishDate |
2020-02-01 |
description |
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and in an effort to identify novel therapeutic target for this disease in recent years, human microbiota has attracted much interest. This paper briefly summarizes the main findings concerning the differences of human microbiome across several important mucosal interfaces, including nose, mouth, and gut between PD patients and controls as obtained from a total of 13 studies published since 2015, which covered a total of 943 PD patients and 831 matched controls from 6 countries. Overall, these studies supported the differences of gut microbiota between PD patients and matched controls, while significantly altered bacterial taxa among studies were not identical. Due to relatively limited number of available studies and covered patients, the associations between oral and nasal microbiota and PD remain inconclusive. The therapeutic and diagnostic potentials of gut microbiota for PD are discussed. More well-designed clinical studies recruiting large-scale PD patients are encouraged in future. |
topic |
Parkinson’s disease Gut microbiota Oral microbiota Nasal microbiota |
url |
http://link.springer.com/article/10.1186/s12934-020-01313-4 |
work_keys_str_mv |
AT liangshen gutoralandnasalmicrobiotaandparkinsonsdisease |
_version_ |
1724912205726482432 |